Drug Profile
Research programme: hydroxysteroid dehydrogenase inhibitors - Ipsen
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ipsen
- Class
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Metabolic syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-syndrome in France
- 26 Jan 2007 Preclinical trials in Metabolic syndrome in France (unspecified route)